nav-left cat-right
cat-right

Developing a New Blood Test for Multiple Sclerosis

DioGenix formed an alliance with Fast Forward, a subsidiary of the National Multiple Sclerosis Society, to develop a novel blood test for multiple sclerosis (MS). Fast Forward will provide up to $500,000 as part of a Sponsored Research Agreement that will enable DioGenix to expand an ongoing clinical trial of its MS diagnostic, MSPrecise™, a next-generation sequencing assay that measures changes to the adaptive immune...

Horizon Applies Gene Editing to Huntington’s Disea...

Horizon Discovery inked a gene-editing research collaboration with the Institute of Neurology, University College London. The partnership will focus on the creation of human isogenic disease model cell lines with insertion of Huntington’s disease-causing triplet repeats. The company will provide UCL with access to GENESIS, its rAAV-mediated human gene-editing platform. This collaboration is a novel one for Horizon:...

HPV Vaccine Benefits Women with HIV

A vaccine for human papillomavirus (HPV) may benefit women with HIV, even if they have already been exposed to HPV, according to a study released by an NIH research network. The study, published in the Journal of Acquired Immune Deficiency Syndromes in an article titled “Prevalence and Risk Factors for HPV in HIV-Positive Young Women Receiving Their First HPV Vaccination”, notes that more than 45% of women...

XenoPort and GSK End Horizant Collaboration

XenoPort has reached an agreement with Glaxo Group (GSK) to terminate their collaboration agreement concerning Horizant® (gabapentin enacarbil) extended-release tablets, for which GSK held commercialization rights and certain development rights in the United States. GSK is returning Horizant rights to XenoPort and providing certain assistance during a transition period. The termination and transition agreement also...

Immune Pharmaceuticals Merges with EpiCept

Immune Pharmaceuticals and EpiCept have agreed to merge. The combined company, to be named Immune Pharmaceuticals, will be primarily focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer. Immune Pharmaceuticals is an Israel- and U.S.-based biopharmaceutical company focused on the development of next-generation antibody therapeutics addressing unmet...

PROTEROS ANNOUNCES APPOINTMENT OF NEW CHIEF FINANC...

Martinsried, Germany, October 11, 2012. Proteros biostructures GmbH (“Proteros”) today announced the appointment of Mr. Arnd Christ as Chief Financial Officer (CFO) as of 16th of November. Arnd Christ has more than 12 years of international experience as a CFO in the biotechnology industry, with responsibilities in finance, operations, legal affairs and investor relations. He has successfully conducted a number of...
Page 30 of 151« First...1020...2829303132...405060...Last »